187 related articles for article (PubMed ID: 24445938)
1. In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.
Leboeuf C; Mailly L; Wu T; Bour G; Durand S; Brignon N; Ferrand C; Borg C; Tiberghien P; Thimme R; Pessaux P; Marescaux J; Baumert TF; Robinet E
Mol Ther; 2014 Mar; 22(3):634-644. PubMed ID: 24445938
[TBL] [Abstract][Full Text] [Related]
2. Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma.
Wu T; Leboeuf C; Durand S; Su B; Deschamps M; Zhang X; Ferrand C; Pessaux P; Robinet E
Mol Med Rep; 2016 Mar; 13(3):2645-54. PubMed ID: 26820174
[TBL] [Abstract][Full Text] [Related]
3. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo.
Wang FS; Liu MX; Zhang B; Shi M; Lei ZY; Sun WB; Du QY; Chen JM
World J Gastroenterol; 2002 Jun; 8(3):464-8. PubMed ID: 12046071
[TBL] [Abstract][Full Text] [Related]
5. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
6. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model.
Lee DH; Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho E; Lee JH; Yu SJ; Kim YJ; Yoon JH
Cancer Biol Ther; 2017 Jan; 18(1):67-75. PubMed ID: 28055304
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
10. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
[TBL] [Abstract][Full Text] [Related]
11. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
Shi L; Lin H; Li G; Jin RA; Xu J; Sun Y; Ma WL; Yeh S; Cai X; Chang C
Mol Cancer Ther; 2016 Apr; 15(4):731-742. PubMed ID: 26939703
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
13. Taste receptor T1R1/T1R3 promotes the tumoricidal activity of hepatic CD49a
Liu S; Xu M; Zhu C; Zhao Q; Zhou F
Eur J Immunol; 2018 Dec; 48(12):2031-2041. PubMed ID: 30259960
[TBL] [Abstract][Full Text] [Related]
14. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.
Goto K; Annan DA; Morita T; Li W; Muroyama R; Matsubara Y; Ito S; Nakagawa R; Tanoue Y; Jinushi M; Kato N
Sci Rep; 2016 Dec; 6():38407. PubMed ID: 27910927
[TBL] [Abstract][Full Text] [Related]
15. hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function.
Jiang W; Zhang C; Tian Z; Zhang J
Gene Ther; 2013 Nov; 20(11):1062-9. PubMed ID: 23759701
[TBL] [Abstract][Full Text] [Related]
16. An Optogenetic Controllable T Cell System for Hepatocellular Carcinoma Immunotherapy.
Zhao B; Wang Y; Tan X; Zheng X; Wang F; Ke K; Zhang C; Liao N; Dang Y; Shi Y; Zheng Y; Gao Y; Li Q; Liu X; Liu J
Theranostics; 2019; 9(7):1837-1850. PubMed ID: 31037142
[No Abstract] [Full Text] [Related]
17. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.
Gauttier V; Judor JP; Le Guen V; Cany J; Ferry N; Conchon S
Int J Cancer; 2014 Dec; 135(12):2857-67. PubMed ID: 24789574
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
19. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
[TBL] [Abstract][Full Text] [Related]
20. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
